TLSI•benzinga•February 19, 2025 at 11:19 AM

Trisalus Life Sciences Entered A $50M, Five-year Credit Agreement With Orbimed, Securing $25M Upfront. An Additional $10M Is Available Until June 30, 2025, And $15M Until December 31, 2025, Contingent On Revenue Targets

No summary available.

Read the full article from the original source for complete details and context.

Article published on February 19, 2025 by benzinga